Status:
COMPLETED
Psilocybin Cancer Anxiety Study
Lead Sponsor:
NYU Langone Health
Conditions:
Cancer
Eligibility:
All Genders
18-76 years
Phase:
EARLY_PHASE1
Brief Summary
The primary objective of this double-blind, placebo-controlled pilot study is to assess the efficacy of psilocybin administration (4-phosphoryloxy-N,N-dimethyltryptamine), a serotonergic psychoactive ...
Eligibility Criteria
Inclusion
- Age: 18-76
- Current or historical diagnosis of cancer
- Projected life expectancy of at least one year
- DSM-IV diagnoses: Acute Stress Disorder, Generalized Anxiety Disorder, Anxiety Disorder due to cancer, Adjustment Disorder with anxious features
- Any stage of cancer diagnosis
Exclusion
- Epilepsy
- Renal disease
- Diabetes
- Abnormal liver function
- Severe cardiovascular disease
- Malignant Hypertension
- Baseline blood pressure must be less than or equal to 140/90
- Personal history or immediate family members with schizophrenia, bipolar affective disorder, delusional disorder, schizoaffective disorder or other psychotic spectrum illness
- Current substance use disorder
- Medication contraindications: anti-seizures medications, insulin, oral hypoglycemics, clonidine, aldomet, cardiovascular medications, anti-psychotics (first and second generation), anti-depressants and mood stabilizers
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 6 2018
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00957359
Start Date
February 1 2009
End Date
September 6 2018
Last Update
October 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU College of Dentistry Bluestone Center for Clinical Research
New York, New York, United States, 10010